anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

226,021-226,080 of 319,975

filter-aware
03
The slide uses a hub-and-spoke diagram where a central image of a fuel cell stack connects to five distinct strategic pillars.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Humble Origins1 hit
04
The slide uses a three-row structure to categorize business activities and a right-hand sidebar for key company metrics.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Humble Origins1 hit
05
Includes technical specifications for three tiers of fuel cell trucks (Short, Medium, Long range).Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Early Struggles1 hit
06
The slide uses a central product image to anchor the comparison between IP metrics on the left and performance metrics on the right.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
07
Uses a vertical timeline-style list to organize four key business pillars.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Early Struggles1 hit
08
The slide uses a visual bridge between the two production milestones.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
09
The slide uses a stacked bar chart for margin and a donut chart for cost breakdown, paired with a numbered list of strategic drivers.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
10
The slide highlights three specific programs: California HVIP, IRA ZE Port Equipment, and the US DoE Hydrogen Hub Program.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
11
The slide uses a dual-section layout: a top table for the ramp-up model and a bottom section for current pipeline status with customer logos.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
12
The slide uses a logo-grid to establish credibility through partner associations.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
13
The chart uses a concentric semi-circle design to represent market layers, with a specific focus on HD trucking as the core.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
14
The slide uses icons to categorize milestones into Organization, Fuel cell, and Vehicle.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
15
The slide uses a hub-and-spoke diagram with a central image of a fuel cell stack.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
16
Hyzon | Investor Conference Presentation Deck | 20 slidesHyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
17
Hyzon | Investor Conference Presentation Deck | 20 slidesHyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
18
The table provides a breakdown of adjustments including fair value changes, stock-based compensation, and one-time charges.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
19
Includes footnotes regarding SEC settlement payments and cash position dates.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
20
The slide uses a before-after donut chart comparison and a supporting table to detail the share movement.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
01
Slide 1
Includes company logo, tagline, mission statement, date, and ticker symbol.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
02
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
03
The slide uses a numbered list format to present key company milestones and clinical data points.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
05
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations 1 hit
07
The slide uses a hub-and-spoke diagram to centralize the problem of neurotoxicity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
Includes flow cytometry plots and bar charts showing efficacy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
09
The slide highlights the structural modification of the binding domain in NXC-201 compared to the reference Abecma.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
10
The slide uses a schematic diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
11
Includes citations from Nature Signal Transduction and Targeted Therapy and Nature Medicine.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
12
The slide uses a combination of bar charts for preclinical data and a summary table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
13
The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
14
The diagram highlights four key clinical outcomes: no Parkinson's-like symptoms, short hospital stays, broad hospital access, and no deaths in clinical trials.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
15
The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
16
The slide uses a biological illustration to highlight structural differences in binding domains and intracellular signaling components.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
17
Includes comparative data points for CAR-T characteristics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
18
The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
19
The slide uses a process flow diagram to connect cellular pathology to clinical manifestations.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
20
The diagram shows a summation of ~29,712 (prevalence) and ~3,040 (derived from incidence) to reach ~32,752 eligible patients.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
21
The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
26
Includes a footnote citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
27
The slide uses a before-and-after visual comparison to illustrate market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
28
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
29
The slide uses a two-column layout to separate milestones for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
30
The slide uses a standard pharmaceutical pipeline table format to communicate clinical progress and regulatory milestones.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
31
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
32
The slide uses a wave-like visual to represent market segments and their associated dollar values.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
34
The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
35
The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
36
The slide uses a two-column layout to contrast clinical outcomes for two different indications, followed by a row of competitor product logos and financial metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
37
The chart illustrates deepening responses in patients treated with NXC-201 over time.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
38
The slide uses a combination of biological pathway diagrams, pharmacokinetic data, and efficacy metrics to demonstrate the therapeutic advantage of IMX-110.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a numbered list format to present clinical milestones and market opportunities.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
40
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
41
Uses icon-based visualization to represent market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a process flow diagram to illustrate dose escalation steps.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit